RT Journal Article
SR Electronic
T1 Pragmatic, open-label, single-center, randomized, phase II clinical trial to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus in patients with severe pneumonia secondary to COVID-19: the TACROVID trial protocol
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.09.21249263
DO 10.1101/2021.01.09.21249263
A1 Solanich, X
A1 Antolí, A
A1 Padullés, N
A1 Fanlo-Maresma, M
A1 Iriarte, A
A1 Mitjavila, F
A1 Capdevila, O
A1 Molina, M
A1 Sabater, J
A1 Bas, J
A1 Mensa-Vilaró, A
A1 Niubó, J
A1 Calvo, N
A1 Bolivar, S
A1 Rigo-Bonnin, R
A1 Arregui, L
A1 Tebé, C
A1 Hereu, P
A1 Videla, S
A1 Corbella, X
YR 2021
UL http://medrxiv.org/content/early/2021/01/12/2021.01.09.21249263.abstract
AB Introduction Some COVID-19 patients evolve to severe lung injury and systemic hyperinflammatory syndrome triggered by both the coronavirus infection and the subsequent host-immune response. Accordingly, the use of immunomodulatory agents has been suggested but still remains controversial. Our working hypothesis is that methylprednisolone pulses and tacrolimus may be an effective and safety drug combination for treating severe COVID-19 patients.Methods and analysis TACROVID is a randomized, open-label, single-center, phase II trial to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus plus standard of care (SoC) versus SoC alone, in patients at advanced stage of COVID-19 disease with lung injury and systemic hyperinflammatory response. Patients are randomly assigned (1:1) to one of two arms (42 patients in each group). The primary aim is to assess the time to clinical stability after initiating randomization. Clinical stability is defined as body temperature ≤ 37.5°C, and PaO2/FiO2 > 400 and/or SatO2/FiO2 > 300, and respiratory rate ≤24 rpm; for 48 consecutive hours.Discussion Methylprednisolone and tacrolimus might be beneficial to treat those COVID-19 patients progressing into severe pulmonary failure and systemic hyperinflammatory syndrome. The rationale for its use is the fast effect of methylprednisolone pulses and the ability of tacrolimus to inhibit both the CoV-2 replication and the secondary cytokine storm. Interestingly, both drugs are low-cost and can be manufactured on a large scale; thus, if effective and safe, a large number of patients could be treated in developed and developing countries.Trial registration number NCT04341038 / EudraCT: 2020-001445-39Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04341038Funding StatementNo external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study received the ethics approval by the Research Ethics Committee of Bellvitge University Hospital (AC010/20).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to the manuscript are available upon request to the corresponding authorCoVCoronavirusSARS-CoVSevere Acute Respiratory Syndrome CoronavirusMERS-CoVMiddle East Respiratory Syndrome CoronavirusSARS-CoV-2Severe Acute Respiratory Syndrome Coronavirus 2COVID-19Coronavirus disease 2019SoCStandard of CarePaO2arterial oxygen partial pressureSatO2Oxygen saturationFiO2fractional inspired oxygenPICpro-inflammatory cytokinesHLHhemophagocytic lymphohistiocytosisCADMclinically amyopathic dermatomyositisMDA-5anti- melanoma differentiation-associated gene 5RT-PCRReverse transcription polymerase chain reactionLDHlactate dehydrogenaseCRPc-reactive proteinALTalanine aminotransferaseICFinformed consent formECMOextracorporeal membrane oxygenationGFRGlomerular filtration rateBMIbody mass indexPSIPneumonia Severity IndexSOFA scoreSequential Organ Failure Assessment Score6MWTsix-minute walk testeCRFelectronic case report formARDSacute respiratory disease syndromeJAKJanus KinaseILinterleukinBUHBellvitge University Hospital